From Research to the Real World: Moving Prostate Cancer Biomarkers into the Clinic.

Q4 Biochemistry, Genetics and Molecular Biology

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI:10.1615/CritRevOncog.2022043394

Kate Mahon

引用次数: 0

Abstract

Effective biomarkers provide the potential to significantly improve treatment decisions and outcomes in prostate cancer patients. While the literature is inundated with prostate cancer biomarkers in the early phases of testing, very few reach the clinic. Research should be focused on progressing effective biomarkers from discovery to clinical utility and implementation. Presented here is an overview of the biomarker development pathway and a discussion of the current issues impeding our efforts to deliver biomarkers that improve clinical outcomes in men with prostate cancer.

查看原文本刊更多论文

从研究到现实世界:将前列腺癌生物标志物转移到临床。

有效的生物标志物提供了显著改善前列腺癌患者治疗决策和预后的潜力。虽然文献中充斥着早期检测阶段的前列腺癌生物标记物，但很少能进入临床。研究应侧重于从发现到临床应用和实施的有效生物标志物的进展。本文概述了生物标志物的发展途径，并讨论了目前阻碍我们努力提供改善前列腺癌男性临床结果的生物标志物的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical Reviews in Oncogenesis Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

1.70

自引率

0.00%

发文量

期刊介绍： The journal is dedicated to extensive reviews, minireviews, and special theme issues on topics of current interest in basic and patient-oriented cancer research. The study of systems biology of cancer with its potential for molecular level diagnostics and treatment implies competence across the sciences and an increasing necessity for cancer researchers to understand both the technology and medicine. The journal allows readers to adapt a better understanding of various fields of molecular oncology. We welcome articles on basic biological mechanisms relevant to cancer such as DNA repair, cell cycle, apoptosis, angiogenesis, tumor immunology, etc.